Predictive value of early and late residual 18F-fluorodeoxyglucose and 
18F-fluorothymidine uptake using different SUV measurements in patients with 
non-small-cell lung cancer treated with erlotinib

Kobe, Carsten; Scheffler, Matthias; Holstein, Arne; Zander, Thomas; Nogova, Lucia; Lammertsma, Adriaan A.; Boellaard, Ronald; Neumaier, Bernd; Ullrich, Roland T.; Dietlein, Markus; Wolf, Johanna; Kahraman, Deniz

doi:10.1007/s00259-012-2118-8

Local TagsRelease HistoryDetailsSummary

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

Kobe, C., Scheffler, M., Holstein, A., Zander, T., Nogova, L., Lammertsma, A. A., et al. (2012). Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. European Journal of Nuclear Medicine and Molecular Imaging, 39(7), 1117-1127. doi:10.1007/s00259-012-2118-8.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D867-1 Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-D868-0

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Kobe, Carsten¹, Author
Scheffler, Matthias¹, Author
Holstein, Arne¹, Author
Zander, Thomas², Author
Nogova, Lucia¹, Author
Lammertsma, Adriaan A.¹, Author
Boellaard, Ronald¹, Author
Neumaier, Bernd³, Author
Ullrich, Roland T.², Author
Dietlein, Markus⁴, Author
Wolf, Johanna¹, Author
Kahraman, Deniz¹, Author

Affiliations:
1a Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany b Center for Integrated Oncology Cologne Bonn, Cologne, Germany c Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany d Department of Nuclear Medicine and PET Research, VU University Medical Center Amsterdam, Amsterdam, Netherlands e Department of Nuclear Medicine, Center for Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, 50924, Germany, ou_persistent22
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663
3Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149672
4Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149668

Content

show

hide

Free keywords: -

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2012

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: eDoc: 609302
DOI: 10.1007/s00259-012-2118-8

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: European Journal of Nuclear Medicine and Molecular Imaging

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: -

Pages: - Volume / Issue: 39 (7) Sequence Number: - Start / End Page: 1117 - 1127 Identifier: ISSN: 16197070